Rhythm Pharma knocked off stride as mixed PhIII obesity data for its sole big drug look ‘meh’ to many
Just a few weeks after Rhythm Pharmaceuticals $RYTM snagged an FDA OK for setmelanotide in 3 rare genetic disorders that trigger obesity, the biotech is struggling to make a good case for a crucial market expansion.
Rhythm CEO David Meeker spotlighted the positive data at hand for Bardet-Biedl syndrome and Alström syndrome, two other ailments that trigger an insatiable hunger. But their 3 patients with Alström syndrome all failed the primary endpoint in the study while the BBS efficacy rate dwindled significantly from its Phase II results, dragging down the overall results that left investors and analysts wondering just how big this success really was.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.